



Alexopoulos et al. Cardiovascular Diabetology  (2015) 14:68 
DOI 10.1186/s12933-015-0232-1ORIGINAL INVESTIGATION Open AccessDiabetes mellitus and platelet reactivity in
patients under prasugrel or ticagrelor treatment:
an observational study
Dimitrios Alexopoulos*, Chrysoula Vogiatzi, Katerina Stavrou, Niki Vlassopoulou, Angelos Perperis,
Ioanna Pentara and Ioanna XanthopoulouAbstract
Background: The influence of diabetes mellitus (DM) on platelet reactivity (PR) in prasugrel or ticagrelor treated
patients is not well studied.
Methods: In an observational study involving 777 patients with acute coronary syndrome undergoing percutaneous
coronary intervention treated by either prasugrel 10 mg od (n = 315) or ticagrelor 90 mg bid (n = 462), platelet function
was assessed using the VerifyNow P2Y12 function assay (in PRU) at one month post intervention.
Results: In the overall population, ticagrelor and insulin-treated DM affected PR, with a decrease in log by 0.88
(corresponding to a 58 % decrease in PR) compared to prasugrel-treated patients (p < 0.001), and an increase in
log by 0.26 (corresponding to a 30 % increase in PR) compared to non-diabetic patients (p = 0.01), respectively. PR in
prasugrel-treated patients differed significantly by DM status: 70.0 (36.3-113.0) in non-diabetic vs 69.0 (44.5-115.3) in non
insulin-treated diabetic vs 122.0 (69.0-161.0) in insulin-treated diabetic patients, p for trend = 0.01. No differences were
observed in ticagrelor-treated patients. By multivariate analysis, in prasugrel-treated patients insulin-treated DM was the
only factor predicting PR, with log of PR increased by 0.42 (corresponding to a 52 % increase in PR) compared to
non-diabetic patients (p = 0.001). No factor was found to affect PR in ticagrelor-treated patients.
Conclusions: Patients with insulin-treated DM treated with prasugrel post PCI have higher PR, than patients without
DM or non insulin-treated diabetic patients treated with this drug. Ticagrelor treated patients have overall lower PR than
patients on prasugrel, independent of DM status or insulin treatment.
Trial registration: Clinical Trials Gov. NCT01774955
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Patients with type 2 diabetes mellitus (DM) present with
a prothrombotic state, for which platelet dysfunction is
heavily implicated [1]. Despite a considerable variation
of its antiplatelet effects among individuals, clopidogrel
is the most commonly used P2Y12 receptor blocker in
patients undergoing percutaneous coronary intervention
(PCI), including those with DM [2]. High platelet re-
activity (HPR) while on clopidogrel is more prevalent in
diabetic compared with non- diabetic patients, with
platelet reactivity (PR) levels and HPR frequency being* Correspondence: dalex@med.upatras.gr
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creativecommons.org/publicdomain/zero/1.0/highest among those patients requiring insulin therapy
[3–5]. Moreover, DM presence has been identified as a
strong predictor of major adverse cardiovascular events
following PCI with stent implantation, while insulin
treatment is recognized as an additional risk factor for
stent thrombosis [6–9].
Prasugrel and ticagrelor are novel P2Y12 receptor
blockers with more intensive and consistent than clopi-
dogrel antiplatelet activity, introduced into clinical prac-
tice following the Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel–Thrombolysis in Myocardial Infarction
(TRITON-TIMI) 38 and Platelet Inhibition and patient
Outcomes (PLATO) trial, respectively [10, 11]. Noveless article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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of a higher bleeding potential. In the diabetic subpopula-
tions, prasugrel and ticagrelor reduced the primary end-
point – a composite of cardiovascular death, myocardial
infarction, or stroke - compared to clopidogrel by 30 %
and 12 % respectively, without significant DM status-by-
treatment interactions (p for interaction 0.09 and 0.49,
respectively) [12, 13]. In TRITON-TIMI 38, a benefit of
prasugrel over clopidogrel was observed regardless of
whether subjects with DM were treated with insulin or
not, although the absolute benefit was greater in insulin–
treated DM patients (relative risk reduction by 37 % vs
26 %). Similarly, in PLATO trial ticagrelor, when com-
pared with clopidogrel, reduced ischaemic events irre-
spective of diabetic status (p for interaction = 0.3), though
the relative risk reduction was 22 % in insulin-treated vs
7 % in non insulin-treated patients.
In 2 previous randomized, pharmacodynamic studies,
exclusively in diabetic patients, ticagrelor was found to
provide lower PR compared to prasugrel [14, 15]. How-
ever, it is not clear whether DM is included among factors
potentially influencing PR while on treatment with prasu-
grel or ticagrelor. DM was not reported among factors af-
fecting PR under prasugrel in some, though not in all
studies, while prasugrel pharmacokinetics was not influ-
enced by DM status in TRITON-TIMI 38 [16–20]. More-
over, in patients under ticagrelor therapy, DM was not
among factors influencing PR [19, 21]. Furthermore, the
impact of insulin therapy on PR in DM patients treated
with novel P2Y12 receptors blockers has not been previ-
ously analyzed. In the present study we aimed to analyze
factors affecting PR in patients post PCI and under
chronic maintenance dose of either prasugrel or ticagrelor,
with particular emphasis on DM effect and the impact of
insulin therapy.
Methods
This is a cross-sectional, observational study in consecu-
tive patients with acute coronary syndrome undergoing
PCI who were discharged either on prasugrel 10 mg od
or ticagrelor 90 mg bid and had platelet function assess-
ment at one month post intervention. All patients par-
ticipated in an ongoing study of platelet function testing
for prediction of bleeding events (Clinical Trials Gov.
NCT01774955), while part of PR data have been previ-
ously reported [19]. Platelet function testing was per-
formed using the VerifyNow (Accumetrics Inc., San
Diego, CA, USA) P2Y12 function assay, measured in
P2Y12 reaction units (PRU). An intra-assay variability
of 2.1 ± 1.3 % with a 6 % coefficient of variation has
been described [22]. HPR was defined as >208 PRU
[23]. Blood samples were obtained 2–4 h after the last
drug dose. All patients were encouraged to receive pra-
sugrel or first ticagrelor dose between 8 and 9 a.m. andsecond ticagrelor dose after 12 h. All patients were self-
reported as compliant to therapy at one-month follow-up
and received the same treatment as at discharge. Previ-
ously used definitions for DM, hypertension, dyslipidemia
and myocardial infarction were employed [24–27].
Statistical analysis
Categorical data are presented as frequencies and group
percentages. Continuous data with normal and skewed
distribution are presented as means ± standard deviation
(SD) and medians (first to third quartile) respectively. One-
way analysis of variance and Fisher’s exact test were used
for comparison of normally distributed continuous and cat-
egorical data respectively. The Kruskal-Wallis test was used
for comparison of skewed continuous data. Platelet reactiv-
ity differences between groups in the overall population
and separately among ticagrelor and prasugrel-treated pa-
tients were analyzed via a generalized linear model with
gamma distribution and logarithmic transformation of the
dependent variable, DM status/type of treatment (insulin
treated DM vs non-DM and non-insulin treated DM vs
non-DM), male gender, statin use, proton pump inhibitor
use, current smoking, hypertension, admission with ST-
segment elevation myocardial infarction, creatinine clear-
ance < 60 ml/min and treatment with ticagrelor (only for
the overall population) as fixed effects and age and body
mass index as covariates. All independent variables were
simultaneously included in the model. The exponentiated
coefficient represents the factor by which PR is multiplied.
All patients provided written informed consent. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori ap-
proval by the institution’s human research committee.
Results
Among 777 analyzed patients, 315 and 462 were on prasu-
grel and ticagrelor maintenance dose respectively. Patients’
characteristics by DM status and type of treatment are
presented in Table 1.
In the overall population, 2 factors were found inde-
pendently affecting PR at one month: i) Treatment with
ticagrelor, with log of PR decreased by 0.88 (corresponding
to a 58 % decrease in PR) compared to prasugrel-treated
patients and ii) insulin-treated DM, with log of PR in-
creased by 0.26 (corresponding to a 30 % increase in PR)
compared to non-diabetic patients (Table 2).
Patients’ individual PR values by DM status and type of
treatment separately for ticagrelor and prasugrel-treated
patients are presented in Fig. 1. Platelet reactivity (PRU)
among prasugrel-treated patients differed significantly:
70.0 (36.3-113.0) in non diabetic vs 69.0 (44.5-115.3) in
non insulin-treated diabetic vs 122.0 (69.0-161.0) in
insulin-treated diabetic patients, p for trend = 0.01. In con-
trast, among ticagrelor-treated patients, PR did not differ
Table 1 Demographic and clinical characteristics of patients by diabetic status and type of treatment
No diabetes mellitus Diabetes mellitus non insulin-treated Diabetes mellitus insulin-treated p-value
N = 603 N = 132 N = 42
Male gender 519 (86.1) 116 (87.9) 38 (90.5) 0.7
Age (years) 58.9 ± 11.2 63.4 ± 10.4 62.8 ± 10.5 <0.001
Body mass index (Kg/m2) 28.1 ± 4.2 29.2 ± 4.5 29.2 ± 5.7 0.01
Dyslipidemia 300 (49.8) 72 (54.5) 19 (45.2) 0.5
Hypertension 286 (47.4) 94 (71.2) 21 (50.0) <0.001
Current smoking 39 (6.5) 4 (3.0) 2 (4.8) 0.3
Prior myocardial infarction 45 (7.5) 10 (7.6) 4 (9.5) 0.8
Prior CABG 9 (1.5) 2 (1.5) 2 (4.8) 0.3
Prior PCI 58 (9.6) 12 (9.1) 4 (9.5) 1.0
Prior stroke/TIA 10 (1.7) 6 (4.5) 1 (2.4) 0.2
Admission for PCI 0.2
STEMI 342 (56.7) 63 (47.7) 26 (61.9)
NSTEMI 161 (26.7) 40 (30.3) 7 (16.7)
Unstable angina 100 (16.6) 29 (22.0) 9 (21.4)
Creatinine clearance <60 ml/min 51 (8.5) 18 (13.6) 11 (26.2) 0.001
P2Y12 receptor blocker at discharge and follow-up 0.7
Ticagrelor 363 (60.2) 76 (57.6) 23 (54.8)
Prasugrel 240 (39.8) 56 (42.4) 19 (45.2)
Other discharge medication*
Aspirin 100 mg 598 (99.2) 131 (99.2) 42 (100) 1.0
Statin 595 (98.7) 128 (97.0) 40 (95.2) 0.09
Proton pump inhibitor 572 (94.9) 120 (90.9) 34 (81.0) 0.002
Beta-blocker 565 (93.7) 121 (91.7) 40 (95.2) 0.7
Nitrate 66 (10.9) 20 (15.2) 8 (19.0) 0.1
Data are expressed as means ± SD, medians (first to third quartiles) or n (%). CABG = coronary artery bypass grafting; NSTEMI = non ST segment elevation
myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST segment elevation myocardial infarction; TIA = transient ischemic attack
*No patient was on oral anticoagulant treatment
Table 2 Multivariate analysis of platelet reactivity in the overall population
Coefficient (SE) t 95 % CI Exponentiated coefficient* p-value
Male gender 0.04 (0.09) 0.24 −0.13 to 0.21 1.04 0.6
Current smoking −0.15 (0.12) 1.48 −0.39 to 0.09 0.86 0.2
-Insulin-treated diabetes mellitus (vs non-diabetic status) 0.26 (0.11) 6.03 0.053 to 0.47 1.30 0.01
-Non insulin-treated diabetes mellitus (vs non-diabetic status) 0.04 (0.07) 0.34 −0.10 to 0.18 1.04 0.6
Ticagrelor (vs prasugrel) −0.88 (0.06) 217.9 −0.99 to −0.76 0.42 <0.001
Age 0.001 (0.003) 0.08 −0.005 to 0.007 1.001 0.8
Body mass index 0.006 (0.007) 0.88 −0.007 to 0.019 1.006 0.4
Creatinine clearance < 60 ml/min 0.10 (0.09) 1.09 −0.09 to 0.29 1.1 0.3
Statin 0.24 (0.18) 1.79 −0.11 to 0.60 1.27 0.2
Proton pump inhibitor 0.11 (0.12) 0.75 −0.14 to 0.35 1.11 0.4
Hypertension 0.04 (0.06) 0.41 −0.08 to 0.16 1.04 0.5
STEMI at admission −0.11 (0.06) 3.10 −0.23 to 0.01 0.90 0.08
SE = standard error, CI = confidence interval, STEMI = ST-segment elevation myocardial infarction. *Exponentiated coefficient = e^Coefficient is the factor by which PR
on the original scale is multiplied
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Fig. 1 Patients’ individual platelet reactivity values by diabetic status and type of treatment separately for ticagrelor and prasugrel-treated patients;
lines represent medians and error bars inter-quartile range. DM = diabetes mellitus
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vs 31.5 (16.3-53.8) in non insulin-treated diabetic vs 33.0
(10.0-47.0) in insulin-treated diabetic patients, p = 0.1.
In the subgroup of prasugrel-treated patients, DM status
had an overall significant effect on PR (p = 0.002). By
multivariate analysis, insulin-treated DM was the only fac-
tor with a significant effect on PR, with log of PR in-
creased by 0.42 (corresponding to a 52 % increase in PR)
compared to non diabetic patients. Non-insulin treated
DM had no such impact on PR (Table 3). No factor was
found to affect PR in ticagrelor-treated patients (Table 4).Table 3 Multivariate analysis of platelet reactivity in patients under p
Coefficient
Male gender 0.07 (0.14)
Current smoking 0.01 (0.16)
-Insulin-treated diabetes mellitus (vs non-diabetic status) 0.42 (0.12)
-Non insulin-treated diabetes mellitus (vs non-diabetic status) 0.03 (0.11)
Age 0.001 (0.004
Body mass index 0.02 (0.009)
Creatinine clearance < 60 ml/min −0.07 (0.18)
Statin −0.03 (0.38)
Proton pump inhibitor 0.14 (0.19)
Hypertension 0.07 (0.08)
STEMI at admission −0.12 (0.08)
Abbreviations as in Table 2Among prasugrel-treated patients, HPR rates were 3.3 %
(8/240) in non-diabetic, 7.1 % (4/56) in non insulin-treated
diabetic and 10.5 % (2/19) in insulin-treated diabetic
patients (p for trend = 0.1). No ticagrelor-treated patient
presented with HPR.
Discussion
In patients with acute coronary syndrome undergoing PCI
and receiving maintenance prasugrel or ticagrelor therapy
for 1 month, apart from a lower degree of PR provided
by ticagrelor vs prasugrel, this study demonstrates thatrasugrel
(SE) t 95 % CI Exponentiated coefficient* p-value
0.25 −0.21 to 0.35 1.07 0.6
0.003 −0.31 to 0.33 1.01 0.9
12.0 0.18 to 0.65 1.52 0.001
0.09 −0.19 to 0.25 1.03 0.8
) 0.02 −0.007 to 0.008 1.001 0.9
3.35 −0.001 to 0.033 1.02 0.07
0.15 −0.42 to 0.28 0.93 0.7
0.006 −0.77 to 0.71 0.97 0.9
0.58 −0.22 to 0.50 1.15 0.4
0.88 −0.08 to 0.22 1.07 0.4
2.0 −0.27 to 0.04 0.89 0.2
Table 4 Multivariate analysis of platelet reactivity in patients under ticagrelor
Coefficient (SE) t 95 % CI Exponentiated coefficient* p-value
Male gender 0.04 (0.11) 0.15 −0.17 to 0.26 1.04 0.7
Current smoking −0.19 (0.15) 1.54 −0.48 to 0.11 0.83 0.2
-Insulin-treated diabetes mellitus (vs non-diabetic status) 0.10 (0.18) 0.28 −0.26 to 0.45 1.11 0.6
-Non insulin-treated diabetes mellitus (vs non-diabetic status) 0.08 (0.10) 0.74 −0.11 to 0.27 1.08 0.4
Age 0.001 (0.005) 0.04 −0.008 to 0.01 1.001 0.9
Body mass index −0.002 (0.01) 0.03 −0.02 to 0.02 0.998 0.9
Creatinine clearance < 60 ml/min 0.20 (0.12) 2.98 −0.03 to 0.43 1.22 0.08
Statin 0.33 (0.19) 2.99 −0.04 to 0.71 1.39 0.08
Proton pump inhibitor 0.07 (0.17) 0.18 −0.26 to 0.41 1.07 0.7
Hypertension 0.006 (0.09) 0.005 −0.17 to 0.18 1.006 0.9
STEMI at admission −0.12 (0.09) 1.80 −0.29 to 0.05 0.89 0.2
Abbreviations as in Table 2
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differentiated (higher) in insulin-treated diabetic patients,
while they are similar between non-diabetic and non
insulin-treated diabetic patients and ii) ticagrelor provides
an homogeneous, very strong platelet inhibition, not influ-
enced by DM status or insulin/non-insulin treatment.
Several recent studies have emphasized the complex
interaction between DM and platelet function. A higher
mean platelet volume was found in patients with predia-
betes than in normal subjects, which is positively associ-
ated with fasting plasma levels [28]. In this cohort also, a
common platelet antigen polymorphism [PLA1A2] of
the gene encoding Glycoprotein IIIa has been associated
with mortality when HbA1c is ranging from 5.5 % to
6.5 %, and maintenance of euglycemia and antiplatelet
therapy are regarded as effective primary prevention
measures [29]. Of note, in stable patients undergoing
PCI, the variability of on-treatment platelet function and
associated outcome is mainly influenced by clinical risk
variables, including DM [30]. In addition, in type 2 dia-
betic patients, younger age is the most important predictor
of high on-aspirin platelet reactivity [31]. Moreover, differ-
ent anti-diabetic combination therapies seem to differen-
tially affect platelet function. In metformin-treated type 2
diabetic patients, add-on therapy with pioglitazone was
found to be more effective than glipizide for inhibiting
platelet activation [32].
In line with previous reports, in the present study in a
large cohort of patients under prasugrel or ticagrelor
maintenance dose, including 174 patients with DM, and
after adjusting for several factors, treatment with ticagrelor
independently predicted lower PR [19, 33]. Of note, in a
recent network meta-analysis ticagrelor was reported to
achieve significantly lower on-treatment PR compared
with prasugrel, with both being superior to clopidogrel
standard or high dose [34]. Most importantly and, to
our knowledge for the first time, the current analysisdemonstrates a positive relation between insulin-treated
DM and PR in patients receiving maintenance therapy
with novel antiplatelet agents. In addition, this impact
seems to be defined in the prasugrel-treated cohort.
PR under prasugrel treatment
Previous studies of factors affecting PR while on prasugrel
therapy provided conflicting or unclear results concerning
the impact of DM on it, without analyzing the type of DM
treatment effect [16–19]. Among 444 prasugrel-treated
patients with acute coronary syndrome undergoing PCI
and assessed 2 to 4 weeks after hospital discharge, patients
with DM had higher vasodilator-stimulated phosphopro-
tein (VASP) index than non-DM patients, but this effect
was not present in multivariate analysis [16]. In a previous
analysis, by our group, of 234 patients under prasugrel
maintenance dose, constituting part of the present cohort,
and assessed by the VerifyNow, DM had a significant ef-
fect on PR with 36.3 % increase compared to non-DM
patients [19]. In the present larger cohort, DM effect on
prasugrel pharmacodynamics is further elucidated and
seems to be mostly confined in insulin-treated diabetic
patients.
Several explanations could be discussed for the above
findings. Platelets of diabetic patients present with a de-
creased sensitivity to insulin, upregulation of the P2Y12
pathway and increased reactivity. Mechanisms like in-
creased exposure to ADP, increased cytosolic levels of
calcium, and increased platelet turnover may also be im-
plicated in the response to P2Y12 receptor blockers in DM
patients [1, 35]. These abnormalities are likely more pro-
nounced in the insulin-treated diabetic patient [5] and
may partially explain the observed impact on PR under
prasugrel. Moreover, and concerning the other thienopyri-
dine, clopidogrel, active metabolite kinetic profile-and to a
lesser degree platelet dysfunction-seem to be mostly re-
sponsible for the overall impaired platelet P2Y12 receptor
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pharmacokinetic analysis in 1159 patients participating in
the TRITON-TIMI 38 trial, the systemic exposure to pra-
sugrel was not appreciably affected by DM status [20]. Of
note, a separate analysis of prasugrel active metabolite kin-
etics for insulin-treated diabetic was not performed. It
seems therefore that our findings of a neutral and a nega-
tive impact of non insulin-treated DM and insulin-treated
DM on PR respectively, could be attributed to platelet dys-
function in the latest high risk subgroup which cannot be
entirely overcome by the potent antiplatelet thienopyri-
dine prasugrel. In the largest so far pharmacodynamic
study of patients under prasugrel maintenance treatment,
an HPR rate of 10-15 % has been described, although not
stratified by DM status [36]. In the present study, HPR
rate under prasugrel therapy was slightly lower, while a
trend for a progressive increase according to DM status
and type of treatment was apparent.
PR under ticagrelor treatment
In a patient-level data meta-analysis of 8 studies involving
445 ticagrelor-treated patients, DM did not emerge as a fac-
tor predicting PR, although independently associated with
lower probability for PR <10 PRU [21]. In line, in the
present analysis, among ticagrelor-treated patients, no sign
of any influence on PR by DM was seen, even in the high
risk group of insulin-treated diabetic patients. Hence,
insulin-treated DM status may impact the thienopyridines
clopidogrel and prasugrel action, but not ticagrelor’s one,
which is a cyclopentyltriazolo-pyrimidine. Moreover, tica-
grelor is a reversible P2Y12 ADP receptor blocker, adminis-
tered twice daily, which may be more optimal for providing
consistent inhibition for patients with high platelet turnover
rates such as those with DM [37, 38]. Although it is un-
known whether DM status modulates plasma levels of tica-
grelor and its metabolite (AR- C124910XX), the described
absence of any impact on its pharmacodynamics makes it
extremely unlikely. In no case we advocate absence of plate-
let abnormalities following ticagrelor treatment. Only 1 sig-
naling pathway, the P2Y12 one, is blocked by ticagrelor,
leaving multiple other signaling pathways, many known to
be upregulated in DM patients, uninhibited [1].
Clinical relevance
As the great majority of prasugrel- and all of ticagrelor-
treated patients respectively had PR levels below the
threshold known to be accompanied by ischemic events,
our results do not provide a potential explanation why dia-
betic patients and particularly insulin-treated ones have
worse outcomes, despite treatment with novel antiplatelet
agents. The observed detrimental impact of insulin-
treated DM on PR under prasugrel may simply reflect
platelet dysfunction of unclear clinical significance, consid-
ering the excellent performance of this agent in insulin-treated DM in TRITON-TIMI 38- with a 37 % reduction
in the primary endpoint compared to clopidogel [10]. Fur-
thermore, the described impact of insulin-treated DM on
PR under prasugrel is not in discordance with the relative
greater benefit provided by prasugrel in the insulin-treated
diabetic cohort versus non-insulin treated diabetic [12].
This, most likely reflects a considerable ‘weakness’ of clo-
pidogrel in insulin-treated diabetic patients [5]. In the DM
subgroup of the TRITON-TIMI-38 trial, there was no dif-
ference in major bleeding between prasugrel and clopido-
grel treated patients, regardless DM treatment type [12].
Even with the insulin detrimental effect, PR values in our
prasugrel-treated DM patients were much lower than pro-
vided by clopidogrel [36] and are, therefore, unlikely to
provide an explanation for bleeding rates observed in DM
cohort of TRITON-TIMI-38 trial.
HPR under prasugrel, even in insulin-treated diabetic
patients was very low. Nevertheless, its identification
might enable a better understanding of their individual
risk profile and allow the future development of targeted
treatment strategies for these patients. Overall, our study
offers a better understanding of DM status and treat-
ment influence on novel antiplatelets’ pharmacodynamic
behavior, while it demonstrates a differential effect of
insulin-treated DM on PR according to the administered
antiplatelet agent.Limitations
This is a cross-sectional study of independent groups and
suffers from the obvious limitations of a nonrandomized
trial. In an attempt to account for these limitations, we
made adjustment for several clinical variables potentially af-
fecting PR although additional bias cannot be entirely ex-
cluded. Although HbA1C levels were not measured, their
association with PR has been seriously disputed [5, 39].
Genetic variants of the insulin receptor substrate associated
with a hyper-reactive platelet phenotype were not analyzed
[40]. A larger number of patients would increase study’s
power, resulting in more precise estimates. Although
the dynamic range of the VerifyNow assay appears to be
narrower than that of light transmittance aggregometry,
measurements of platelet inhibition while on prasugrel or
ticagrelor using the 2 methods are well correlated [41, 42].Conclusions
Among acute coronary syndrome patients undergoing
PCI and receiving maintenance therapy with prasugrel,
insulin-treated diabetic patients have higher PR than pa-
tients without DM or non insulin-treated diabetic patients.
Ticagrelor treated patients have overall lower PR than pa-
tients on prasugrel, independent of DM status or insulin
treatment. Further study for treatment individualization
according to these findings is guaranteed.
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